ICBM

What ICBM does

ICBM (Instituto de Ciencias Biomédicas) is a public biomedical research institute within the Faculty of Medicine at Universidad de Chile, Chile's oldest public university (founded 1842). It functions as an academic research organization rather than a commercial entity, hosting approximately 140 active researchers across disciplines including parasitology, genetics, immunology, molecular biology, and population health. The institute runs an advanced scientific equipment network called REDECA (Red de Equipamiento Científico Avanzado), executes 88 active research projects, and produces an average of 120 indexed scientific publications annually.

The institute's operations span four primary functions: (1) biomedical research addressing Chilean and regional health challenges including gastric cancer, HIV/AIDS, melanoma, Sjögren's disease, and tropical parasites; (2) biomedical education, administering 73 undergraduate courses, 90 postgraduate courses, and supervising 110 Master's and Doctoral theses, alongside 12,000 direct teaching hours; (3) clinical integration via Hospital Clínico Universidad de Chile, most visibly through the CHAiR (Center for HIV/AIDS Integral Research), which was formalized as a Faculty of Medicine center in January 2026; and (4) inter-institutional research collaborations, including work with Universidad San Sebastián on Sjögren's disease and active participation in global biomedical conferences.

ICBM is funded through public government allocations to Universidad de Chile and competitive national research grants administered by Fondecyt. It does not sell products or services commercially and operates on a non-revenue academic model. Its principal stakeholder relationships are with graduate and undergraduate students receiving biomedical training, the Chilean public healthcare system consuming its research for policy formulation (notably gastric cancer prevention), and the broader international scientific community consuming its peer-reviewed publications. The institute benefits from the parent university's CNA-Chile institutional accreditation at the excellence level, valid through December 2032.

Name

ICBM

Legal name

Instituto de Ciencias Biomédicas (ICBM) - Universidad de Chile

Website

https://icbm.cl

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

ICBM is a public biomedical research institute within Universidad de Chile's Faculty of Medicine, hosting 140 researchers across parasitology, genetics, immunology, and molecular biology. It conducts research, trains biomedical scientists, and supports Chilean public health through 88 active projects and 120 annual publications.

Ownership category

akta.pro rank

Product category

Academic Biomedical Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industry

Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

Keywords

• Biomedical research institute
• Graduate medical education
• Scientific research programs
• Academic biomedical training
• Biomedical science research

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Government University Funding: As part of Universidad de Chile, ICBM receives funding through government allocations for public higher education institutions, supporting research projects, faculty positions, and academic programs.
2. Research Grants (Fondecyt): Competitive national research funding through Fondecyt (Fondo Nacional de Desarrollo Científico y Tecnológico) for specific research projects including initiation grants and ongoing investigations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

ICBM is a biomedical research institute within Universidad de Chile's Faculty of Medicine that conducts scientific research across parasitology, genetics, immunology, molecular biology, paleogenomics, HIV/AIDS, melanoma, and autoimmune diseases. It administers undergraduate, postgraduate, and doctoral academic programs in biomedical sciences, supervises Master's and Doctoral theses, and publishes peer-reviewed scientific articles. The institute operates specialized research centers including CHAiR for HIV/AIDS and runs the TRIMELVax melanoma defense project, supported by the REDECA advanced scientific equipment network.

Product overview

ICBM (Instituto de Ciencias Biomédicas) is a biomedical research institute within the Faculty of Medicine at the University of Chile. The institute functions as an academic research organization rather than a commercial technology company. It offers educational programs at the undergraduate and graduate levels (pregrado and postgrado), conducts biomedical research across multiple disciplines (140 researchers, 88 active research projects), publishes scientific articles (120 indexed articles in 2024), and manages academic courses. Research initiatives include the CHAiR (Center for HIV/AIDS Integral Research) focused on HIV research and education, and the TRIMELVax project for melanoma defense. The institute also provides the Red de Equipamiento Científico Avanzado (REDECA) for shared scientific equipment access.

Differentiator

Problem solved

Functional benefit

Products and services

• Undergraduate Biomedical Academic Programs
• Postgraduate and Doctoral Biomedical Programs
• CHAiR - Center for HIV/AIDS Integral Research Center of the Faculty of Medicine at Universidad de Chile focused on HIV/AIDS research and education, declared as a formal center of the Faculty of Medicine in January 2026 after seven years of operation.
• TRIMELVax Melanoma Defense Research Project Biomedical research project focused on the first line of defense against melanoma.
• Paleogenomics Research Program Fondecyt-funded research initiative analyzing the genomes of individuals who inhabited central Chile up to 7,000 years ago to study genetic diversity and cultural changes.
• REDECA (Red de Equipamiento Científico Avanzado) Network providing ICBM researchers access to advanced scientific equipment and specialized instrumentation shared across research institutions.

Quantifiable outcome

• 120 indexed scientific articles published in 2024
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Universidad San SebastiáncoreStrategic or Co-development PartnerCollaborative research partnership in biomedical sciences. ICBM academics participated in research led by Universidad San Sebastián's Dra. María José Barrera on Sjögren's disease, published in Annals of the Rheumatic Diseases.
• REDECA (Red de Equipamiento Científico Avanzado)coreTechnology or IntegrationNetwork for sharing advanced scientific equipment among research institutions. ICBM researchers utilize REDECA facilities for advanced biomedical research requiring specialized instrumentation.
• Hospital Clínico Universidad de ChilecoreStrategic or Co-development PartnerClinical research partnership with the university's teaching hospital. CHAiR (Center for HIV/AIDS Integral Research) was established as a center of the Faculty of Medicine with hospital integration for clinical research.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Broad Institute of MIT and Harvard: US-based biomedical and genomic research institute affiliated with MIT and Harvard. Comparable to ICBM in genomics and biomedical research, particularly relevant given ICBM's paleogenomics work, though vastly larger in funding and infrastructure scale.
• Institut Pasteur: Historic French biomedical research institute with global reach, conducting fundamental research in infectious diseases, immunology, and developmental biology. Comparable to ICBM in its biomedical research mission and graduate training, but far larger, with international network and broader funding base.
• Karolinska Institutet: Sweden's medical university, one of the world's largest and most prestigious biomedical research and training institutions. Comparable to ICBM in its academic biomedical research and doctoral training focus, but operates at much larger scale and broader international scope.
• Salk Institute for Biological Studies: Independent US non-profit biomedical research institute conducting fundamental research in cancer, neuroscience, immunology, and genetics. Comparable to ICBM in its research-only mission and graduate training via partnerships, though with a much larger endowment and international faculty base.
• Max Planck Institute for Molecular Biomedicine: Germany-based research institute focused on molecular and cellular biomedicine, including vascular biology, stem cells, and inflammation. Comparable to ICBM in conducting basic biomedical research with graduate training, but with substantially larger funding and global recruitment.

Emerging players

• Institut de Recerca Biomèdica (IRB Barcelona): Spanish biomedical research institute focused on computational biology, cancer, and metabolism. Comparable to ICBM in basic biomedical research and graduate training, but newer and smaller, with a more focused thematic research portfolio.

Direct peers

• Instituto de Investigaciones Biomédicas (IIBm), UNAM: Mexico's premier university-based biomedical research institute at UNAM. Directly comparable to ICBM as a Latin American public-university biomedical research institute of similar scope, performing research across molecular biology, immunology, genetics, and parasitology with graduate training programs.

Regional players

• Fundação Oswaldo Cruz (Fiocruz): Brazilian public institution for biomedical research, infectious disease, and public health. Closely comparable to ICBM in its public-sector Latin American biomedical research mission, with parallel focus on HIV/AIDS, parasitology, and population health, though operating at national scale across Brazil.
• Instituto de Biología y Medicina Experimental (IBYME-CONICET): Argentine public biomedical research institute under CONICET, focused on physiology, molecular biology, and reproductive biology. Directly comparable to ICBM as a Latin American biomedical research institute of similar scope and headcount, with graduate training and public-sector funding model.
• Centro de Investigación Biomédica en Red (CIBER): Spanish network of biomedical research consortia coordinated by Instituto de Salud Carlos III. Comparable to ICBM as a public-sector biomedical research network with multi-institutional structure, though operating across Spain with thematic specialization areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/icbm-instituto-de-ciencias-biomedicas

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICBM